Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

医学 化疗 肺癌 肿瘤科 内科学 随机对照试验
作者
Binghao Zhao,Hao Qi,Jiaming Wu,Wenbin Ma
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:18 (7): e72-e73 被引量:1
标识
DOI:10.1016/j.jtho.2023.04.001
摘要

The combination of cemiplimab and platinum-based doublet chemotherapy has received approval for first-line treatment of patients with locally advanced or metastatic NSCLC. The approval was on the basis of the superior efficacy exhibited by cemiplimab in combination with chemotherapy in the primary phase 3 EMPOWER-Lung 3 trial (NCT03409614). 1 Gogishvili M. Melkadze T. Makharadze T. et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022; 28: 2374-2380 Crossref PubMed Scopus (30) Google Scholar The 2-year follow-up results and final overall survival (OS) outcomes recently reported by Makharadze et al. 2 Makharadze T. Gogishvili M. Melkadze T. et al. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: 2-year follow-up from the phase 3 EMPOWER-lung 3 trial. J Thorac Oncol. 2023; 18: 755-768 Abstract Full Text Full Text PDF Scopus (3) Google Scholar have unveiled noteworthy advantages of cemiplimab in combination with chemotherapy, as compared with chemotherapy alone, with regard to OS, progression-free survival, and objective response rate among patients diagnosed with advanced squamous or nonsquamous NSCLC. 2 Makharadze T. Gogishvili M. Melkadze T. et al. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: 2-year follow-up from the phase 3 EMPOWER-lung 3 trial. J Thorac Oncol. 2023; 18: 755-768 Abstract Full Text Full Text PDF Scopus (3) Google Scholar The trial yields promising results; however, before integrating it into clinical practice, several matters should be evaluated. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 TrialJournal of Thoracic OncologyVol. 18Issue 6PreviewEMPOWER-Lung 3 part 2 (NCT03409614), a double-blind, placebo-controlled phase 3 study, investigated cemiplimab (antiprogrammed cell death protein 1) plus chemotherapy versus placebo plus chemotherapy in patients with advanced NSCLC without EGFR, ALK, or ROS1 aberrations, with either squamous or nonsquamous histology, irrespective of programmed death-ligand 1 levels. At primary analysis, after 16.4 months of follow-up, cemiplimab plus chemotherapy improved median overall survival (OS) versus chemotherapy alone (21.9 versus 13.0 mo, hazard ratio [HR] = 0.71, 95% confidence interval [CI]: 0.53–0.93, p = 0.014). Full-Text PDF Open AccessResponse to Letter to the EditorJournal of Thoracic OncologyVol. 18Issue 7PreviewWe thank the readers for their interest in our manuscript reporting protocol-specified final overall survival analysis and 2-year follow-up results from the phase 3 EMPOWER-Lung 3 study.1 In this study, a total of 466 patients with advanced NSCLC (without EGFR, ALK, or ROS1 aberrations) were randomized 2:1 to receive histology-specific platinum-doublet chemotherapy in combination with either 350 mg cemiplimab (n = 312) or placebo (n = 154) every 3 weeks for up to 108 weeks.1,2 At 28.4 months of follow-up, the median overall survival was 21.1 months (95% confidence interval: 15.9–23.5) for cemiplimab plus chemotherapy versus 12.9 months (95% confidence interval: 10.6–15.7) for chemotherapy alone. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
兜兜完成签到,获得积分10
1秒前
糖果发布了新的文献求助10
1秒前
易道聚焦发布了新的文献求助10
1秒前
羞涩的凡梦完成签到 ,获得积分10
1秒前
打打的应助被PYF8086采纳,获得10
1秒前
hmoo发布了新的文献求助10
2秒前
444完成签到,获得积分20
2秒前
123456发布了新的文献求助20
2秒前
2秒前
李李玲发布了新的文献求助10
2秒前
kobe完成签到,获得积分10
2秒前
pp完成签到,获得积分10
3秒前
ocean完成签到,获得积分0
3秒前
3秒前
4秒前
自由的中蓝完成签到 ,获得积分10
5秒前
Akim的应助被wake采纳,获得10
5秒前
银色大跟匙儿完成签到,获得积分20
5秒前
5秒前
5秒前
ran完成签到,获得积分10
5秒前
5秒前
含糊的绝山完成签到,获得积分10
5秒前
三一发布了新的文献求助10
5秒前
5秒前
vip完成签到,获得积分10
5秒前
blue0412完成签到,获得积分10
5秒前
香蕉觅云的应助被stws采纳,获得10
6秒前
6秒前
认真的纸飞机完成签到 ,获得积分10
6秒前
7秒前
迷人的卿发布了新的文献求助10
7秒前
7秒前
搜集达人的应助被Spring采纳,获得10
7秒前
独特的夏蓉完成签到,获得积分10
7秒前
8秒前
lwy发布了新的文献求助10
8秒前
华仔的应助被松本润迷妹采纳,获得20
8秒前
你好发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8167280
求助须知:如何正确求助?哪些是违规求助? 9560076
关于积分的说明 21754886
捐赠科研通 7758257
什么是DOI,文献DOI怎么找? 3429309
关于科研通互助平台的介绍 2553653
邀请新用户注册赠送积分活动 2474136